Evidence map›Paper›PMID 23990779›Full record

ArticlePLoS pathogens2013

Kaposi's sarcoma-associated herpesvirus K-Rta exhibits SUMO-targeting ubiquitin ligase (STUbL) like activity and is essential for viral reactivation.

Yoshihiro Izumiya, Keisuke Kobayashi, Kevin Y Kim, Mamata Pochampalli, Chie Izumiya, Bogdan Shevchenko, Don-Hong Wang, Steve B Huerta, Anthony Martinez, Mel Campbell and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Specificity in Ubiquitination Triggered by Virus Infection.International journal of molecular sciences · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Yoshihiro IzumiyaDepartment of Dermatology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California, United States of America. yizumiya@ucdavis.edu
Keisuke Kobayashi
Kevin Y Kim
Mamata Pochampalli
Chie Izumiya
Bogdan Shevchenko
Don-Hong Wang
Steve B Huerta
Anthony Martinez
Mel Campbell
Hsing-Jien Kung
UC Davis Comprehensive Cancer CenterUniversity of California, Davis · USNational Health Research Institutes · TW

Funding

ORF36 Viral Kinase as a Transcriptional Regulator of KSHVP01DE019085 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SUN, REN · 2008 to 2012
$6.4M
K-Rta as a Novel SUMO and Epigenetic RegulatorR01CA147791 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA147791NCI NIH HHS R01-CA147791NIDCR NIH HHS P01 DE019085NIDCR NIH HHS P01-DE19085
6 · The paper itself

Abstract

The small ubiquitin-like modifier (SUMO) is a protein that regulates a wide variety of cellular processes by covalent attachment of SUMO moieties to a diverse array of target proteins. Sumoylation also plays an important role in the replication of many viruses. Previously, we showed that Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a SUMO-ligase, K-bZIP, which catalyzes sumoylation of host and viral proteins. We report here that this virus also encodes a gene that functions as a SUMO-targeting ubiquitin-ligase (STUbL) which preferentially targets sumoylated proteins for degradation. K-Rta, the major transcriptional factor which turns on the entire lytic cycle, was recently found to have ubiquitin ligase activity toward a selected set of substrates. We show in this study that K-Rta contains multiple SIMs (SUMO interacting motif) and binds SUMOs with higher affinity toward SUMO-multimers. Like RNF4, the prototypic cellular STUbL, K-Rta degrades SUMO-2/3 and SUMO-2/3 modified proteins, including promyelocytic leukemia (PML) and K-bZIP. PML-NBs (nuclear bodies) or ND-10 are storage warehouses for sumoylated proteins, which negatively regulate herpesvirus infection, as part of the intrinsic immune response. Herpesviruses have evolved different ways to degrade or disperse PML bodies, and KSHV utilizes K-Rta to inhibit PML-NBs formation. This process depends on K-Rta's ability to bind SUMO, as a K-Rta SIM mutant does not effectively degrade PML. Mutations in the K-Rta Ring finger-like domain or SIM significantly inhibited K-Rta transactivation activity in reporter assays and in the course of viral reactivation. Finally, KSHV with a mutation in the Ring finger-like domain or SIM of K-Rta replicates poorly in culture, indicating that reducing SUMO-conjugates in host cells is important for viral replication. To our knowledge, this is the first virus which encodes both a SUMO ligase and a SUMO-targeting ubiquitin ligase that together may generate unique gene regulatory programs.

Indexed as

Amino Acid MotifsBasic-Leucine Zipper Transcription FactorsHEK293 CellsHerpesviridae InfectionsHerpesvirus 8, HumanHumansImmediate-Early ProteinsMutationNuclear ProteinsPromyelocytic Leukemia ProteinProtein Structure, TertiaryProteolysisRepressor ProteinsSmall Ubiquitin-Related Modifier ProteinsTrans-ActivatorsTranscription FactorsBasic-Leucine Zipper Transcription FactorsImmediate-Early ProteinsK8 protein, Human herpesvirus 8Nuclear ProteinsPML protein, humanPromyelocytic Leukemia ProteinRepressor ProteinsRta protein, Human herpesvirus 8Small Ubiquitin-Related Modifier ProteinsSUMO2 protein, humanSUMO3 protein, humanTrans-ActivatorsTranscription FactorsTumor Suppressor ProteinsUbiquitin-Protein LigasesUbiquitinsViral Proteins

Identifiers

PMID23990779
PMCPMC3749962
OpenAlexW1973402452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.